EP2408778A1 - Derives de n-[(6-aza-bicyclo[3.2.1]oct-5-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique - Google Patents
Derives de n-[(6-aza-bicyclo[3.2.1]oct-5-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutiqueInfo
- Publication number
- EP2408778A1 EP2408778A1 EP10715933A EP10715933A EP2408778A1 EP 2408778 A1 EP2408778 A1 EP 2408778A1 EP 10715933 A EP10715933 A EP 10715933A EP 10715933 A EP10715933 A EP 10715933A EP 2408778 A1 EP2408778 A1 EP 2408778A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- compound
- phenyl
- treatment
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Definitions
- dC 6 alkyl group represents a carbon chain of 1 to 6 carbon atoms, linear or branched, for example methyl, ethyl, propyl, isopropyl, butyl, te / f-butyl, pentyl, hexyl; alkenyl, a linear or branched, mono- or poly-unsaturated aliphatic group, for example comprising one or two ethylenic unsaturations, -alkoxy, a -O-alkyl group; hydroxy, -OH, alkyl-thio, alkyl-substituted sulfur; halogen atom, fluorine, chlorine, bromine or iodine, haloalkyl, alkyl group of which one or more hydrogen atoms have been substituted by halogen.
- the compounds of the invention exhibit particular activity as inhibitors of Glyti glycine transporters, including an improved activity and safety profile.
- the chiral compounds of general formula (I) can be obtained by separation of the racemic compounds by high performance liquid chromatography (HPLC) on a chiral column, or by separation by chromatography on silica gel of the chiral diastereoisomers of the amine of formula general (IIa) then debenzylation, as described in Scheme 2.
- HPLC high performance liquid chromatography
- the efficacy of the compound is determined by the IC 5 O, concentration of the compound which reduces by 50% the specific capture of glycine, defined by the difference in radioactivity incorporated by the control batch and the batch which received the glycine at 10 mM.
- the compounds of the invention, in this test, have an Cl 50 of the order of 0.1 to 10 ⁇ M.
- the compounds according to the invention can therefore be used for the preparation of medicaments, in particular inhibitory drugs of the glycine glycine transporter.
- the tablets may be bare, sugar-coated, for example with sucrose, or coated with various polymers or other suitable materials. They can be designed to allow rapid, delayed or prolonged release of the active ingredient through polymer matrices or specific polymers used in the coating.
- the capsules may be hard or soft, film-coated or not, so as to have a rapid, prolonged or delayed activity (for example for an enteric form).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0901220A FR2943059A1 (fr) | 2009-03-16 | 2009-03-16 | Derives de n-°6-aza-bicyclo°3.2.1!oct-5-yl)-aryl-methyl!- heterobenzamide,leur preparation et leur application en therapeutique |
PCT/FR2010/050448 WO2010106270A1 (fr) | 2009-03-16 | 2010-03-15 | Derives de n-[(6-aza-bicyclo[3.2.1]oct-5-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2408778A1 true EP2408778A1 (fr) | 2012-01-25 |
Family
ID=40720092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10715933A Withdrawn EP2408778A1 (fr) | 2009-03-16 | 2010-03-15 | Derives de n-[(6-aza-bicyclo[3.2.1]oct-5-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique |
Country Status (17)
Country | Link |
---|---|
US (1) | US20120029027A1 (es) |
EP (1) | EP2408778A1 (es) |
JP (1) | JP2012520346A (es) |
KR (1) | KR20120013325A (es) |
CN (1) | CN102356084A (es) |
AR (1) | AR075838A1 (es) |
AU (1) | AU2010224721A1 (es) |
BR (1) | BRPI1009497A2 (es) |
CA (1) | CA2755528A1 (es) |
FR (1) | FR2943059A1 (es) |
IL (1) | IL215103A0 (es) |
MX (1) | MX2011009746A (es) |
RU (1) | RU2011141760A (es) |
SG (1) | SG174432A1 (es) |
TW (1) | TW201100431A (es) |
UY (1) | UY32496A (es) |
WO (1) | WO2010106270A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
ES2927019T3 (es) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
CN113439078B (zh) | 2019-02-19 | 2024-04-23 | 吉利德科学公司 | Fxr激动剂的固体形式 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2861076B1 (fr) * | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique |
TW200911808A (en) * | 2007-07-23 | 2009-03-16 | Astrazeneca Ab | Novel compounds |
-
2009
- 2009-03-16 FR FR0901220A patent/FR2943059A1/fr active Pending
-
2010
- 2010-03-15 TW TW099107513A patent/TW201100431A/zh unknown
- 2010-03-15 KR KR1020117024140A patent/KR20120013325A/ko not_active Application Discontinuation
- 2010-03-15 SG SG2011066842A patent/SG174432A1/en unknown
- 2010-03-15 JP JP2012500293A patent/JP2012520346A/ja not_active Withdrawn
- 2010-03-15 AR ARP100100801A patent/AR075838A1/es unknown
- 2010-03-15 CA CA2755528A patent/CA2755528A1/fr not_active Abandoned
- 2010-03-15 BR BRPI1009497-0A patent/BRPI1009497A2/pt not_active IP Right Cessation
- 2010-03-15 RU RU2011141760/04A patent/RU2011141760A/ru unknown
- 2010-03-15 WO PCT/FR2010/050448 patent/WO2010106270A1/fr active Application Filing
- 2010-03-15 AU AU2010224721A patent/AU2010224721A1/en not_active Abandoned
- 2010-03-15 CN CN2010800121523A patent/CN102356084A/zh active Pending
- 2010-03-15 EP EP10715933A patent/EP2408778A1/fr not_active Withdrawn
- 2010-03-15 MX MX2011009746A patent/MX2011009746A/es not_active Application Discontinuation
- 2010-03-15 US US13/256,834 patent/US20120029027A1/en not_active Abandoned
- 2010-03-16 UY UY0001032496A patent/UY32496A/es not_active Application Discontinuation
-
2011
- 2011-09-12 IL IL215103A patent/IL215103A0/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2010106270A1 * |
Also Published As
Publication number | Publication date |
---|---|
BRPI1009497A2 (pt) | 2018-03-13 |
FR2943059A1 (fr) | 2010-09-17 |
CA2755528A1 (fr) | 2010-09-23 |
JP2012520346A (ja) | 2012-09-06 |
TW201100431A (en) | 2011-01-01 |
AU2010224721A1 (en) | 2011-10-06 |
UY32496A (es) | 2010-10-29 |
SG174432A1 (en) | 2011-10-28 |
US20120029027A1 (en) | 2012-02-02 |
MX2011009746A (es) | 2011-09-29 |
AR075838A1 (es) | 2011-04-27 |
RU2011141760A (ru) | 2013-04-27 |
WO2010106270A1 (fr) | 2010-09-23 |
KR20120013325A (ko) | 2012-02-14 |
IL215103A0 (en) | 2011-12-29 |
CN102356084A (zh) | 2012-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1680421B1 (fr) | Composes tricycliques comme inhibiteurs de transport de glycine | |
EP1680400B1 (fr) | Derives de n-[ phenyl(pyrrolidin-2-yl)methyl]benzamide, et n-[(azepan-2-yl) phenylmethyl]benzamide, leur preparation et leur application en therapeutique | |
EP1682503B1 (fr) | Derives de n-[phenyl(alkylpiperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
CA2542373A1 (fr) | Derives de n-[phenyl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique | |
WO2003089411A1 (fr) | Derives de n-[phenyl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique | |
EP1527048A2 (fr) | Derives de n- phenyl(piperidin-2-yl)methyl benzamide, leur preparation et leur application en therapeutique | |
EP2408778A1 (fr) | Derives de n-[(6-aza-bicyclo[3.2.1]oct-5-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique | |
WO2008037881A2 (fr) | Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique. | |
WO2010106269A2 (fr) | Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique | |
FR2944283A1 (fr) | Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique | |
EP0522914A1 (fr) | Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique | |
FR2943056A1 (fr) | Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique | |
WO2010119222A1 (fr) | Derives de n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique | |
WO2010092287A1 (fr) | Derives de n-[(6-aza-bicyclo[3.2.1]oct-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique | |
WO2010092286A1 (fr) | Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20111017 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120515 |